Comparing Hemab Therapeutics (COAG) & The Competition

Hemab Therapeutics (NASDAQ:COAG) is one of 860 public companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Hemab Therapeutics to similar companies based on the strength of its earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Hemab Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	1	1	5	0	2.57
Hemab Therapeutics Competitors	9345	14859	44479	1504	2.54

Hemab Therapeutics currently has a consensus price target of $51.40, suggesting a potential upside of 16.87%. As a group, “Biotechnology” companies have a potential upside of 59.04%. Given Hemab Therapeutics’ competitors higher probable upside, analysts clearly believe Hemab Therapeutics has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Hemab Therapeutics and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	-1.77
Hemab Therapeutics Competitors	$684.37 million	$8.93 million	-11.85

Hemab Therapeutics’ competitors have higher revenue and earnings than Hemab Therapeutics. Hemab Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Hemab Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Hemab Therapeutics Competitors	-9,425.33%	-127.47%	-33.08%

Institutional & Insider Ownership

48.0% of shares of all “Biotechnology” companies are held by institutional investors. 12.9% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Hemab Therapeutics beats its competitors on 6 of the 11 factors compared.

About Hemab Therapeutics

We are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Coagulation disorders encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches. Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. We are also advancing multiple preclinical and discovery-stage assets. We estimate that there are approximately an aggregate of 10,000 patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease in the geographies where we intend to commercialize our assets, including the United States, the European Union, Japan, the Gulf Cooperation Council countries and other select regions. With greater disease burden awareness, potential regulatory approvals of new prophylactic options and expanding global reach of these options, we believe the overall number of addressable patients for our clinical-stage assets, and preclinical and discovery stage programs could be greater than we currently estimate. We aim to establish the industry’s leading coagulation franchise through the execution of our “Hemab 2×3 by 2030” strategic roadmap, which is designed to build a franchise consisting of 2 commercial medicines, 2 new late-stage clinical programs, and 2 new early-stage clinical programs by 2030. We have not yet initiated pivotal trials for any of our product candidates, and due to the novel and unproven nature of our programs, their current stage of development and the lack of approved prophylactic therapies to inform endpoint selection and trial design, we may not be able to achieve our strategic goals on the timeline we expect or at all. Our principal executive offices are located in Cambridge, MA.